- Medtronic plc (NYSE:MDT) has launched the Medtronic Extended infusion set in the U.S., the first and only infusion set labeled for up to 7-day wear.
- An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.
- The Medtronic Extended infusion set uses advanced materials that help reduce insulin preservative loss and maintain insulin flow and stability to double the wear time of an infusion set.
- Also read: Medtronic Shares Fall As Blood Pressure Reduction Device Fails On Primary Goal.
- In clinical studies, study participants observed a decrease in the number of times an infusion set needed to be changed by 50%. The number of infusion set failures associated with high glucose levels was lowered.
- Additionally, the Medtronic Extended infusion set is estimated to result in annual cost savings of insulin of up to 25% due to a reduced number of the infusion set and reservoir changes that result in unrecoverable insulin as plastic waste reduction of up to 50%.
- With the U.S. launch of the Medtronic Extended infusion set, this innovation is now available exclusively for customers using MiniMed 600 and 700 series pumps.
- Price Action: MDT shares are up 0.60% at $83.40 on the last check Tuesday.
Lam Research Faces Analyst Scrutiny Over Near-Term Margin and China Demand Uncertainties
Lam Research Corp (NASDAQ: LRCX) reported quarterly earnings of $6.85 per share, which beat the consensus estimate of $6.07.
